International Biotechnology (LON:IBT - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported GBX (5.60) (($0.07)) earnings per share for the quarter, Digital Look Earnings reports. International Biotechnology had a net margin of 90.66% and a return on equity of 13.67%.
International Biotechnology Price Performance
Shares of IBT stock remained flat at GBX 578 ($7.62) during trading hours on Tuesday. 69,089 shares of the stock traded hands, compared to its average volume of 84,333. The company's 50-day moving average price is GBX 594.35 and its two-hundred day moving average price is GBX 662.73. International Biotechnology has a 12 month low of GBX 480 ($6.32) and a 12 month high of GBX 736 ($9.70). The firm has a market cap of £207.63 million, a PE ratio of 5.52 and a beta of 0.21.
Insider Buying and Selling at International Biotechnology
In other news, insider Alexa Henderson bought 6,996 shares of the stock in a transaction on Wednesday, February 19th. The shares were acquired at an average cost of GBX 711 ($9.37) per share, for a total transaction of £49,741.56 ($65,535.65). Insiders own 4.18% of the company's stock.
About International Biotechnology
(
Get Free Report)
The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.
The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider International Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list.
While International Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
